Clinical Trial Update: Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of ON-01910.Na (rigosertib) in patients with myelodysplastic syndrome has been completed, reporting safety and PK data …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED